213 related articles for article (PubMed ID: 21812538)
21. Lymphocyte-predominant Hodgkin disease: a comprehensive overview.
Bose S; Ganesan C; Pant M; Lai C; Tabbara IA
Am J Clin Oncol; 2013 Feb; 36(1):91-6. PubMed ID: 21358294
[TBL] [Abstract][Full Text] [Related]
22. Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA; Engert A
Curr Opin Oncol; 2021 Sep; 33(5):395-399. PubMed ID: 34224482
[TBL] [Abstract][Full Text] [Related]
23. Nodular lymphocyte-predominant Hodgkin lymphoma.
Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Hodgkin lymphoma: a 50-year perspective.
Canellos GP; Rosenberg SA; Friedberg JW; Lister TA; Devita VT
J Clin Oncol; 2014 Jan; 32(3):163-8. PubMed ID: 24441526
[No Abstract] [Full Text] [Related]
25. [Primary treatment of early stage Hodgkin's disease].
Molnár Z; Esik O; Illés A
Orv Hetil; 2005 Jan; 146(2):57-61. PubMed ID: 15724953
[TBL] [Abstract][Full Text] [Related]
26. Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy.
Garciaz S; Harel S; Amorim S; Bouabdallah R; Thieblemont C; Brice P
Br J Haematol; 2016 Nov; 175(4):735-737. PubMed ID: 26685097
[No Abstract] [Full Text] [Related]
27. [Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma].
Dourthe ME; Simonin M; Rigaud C; Haouy S; Montravers F; Ducou Le Pointe H; Garnier N; Minard-Colin V; Jo Molina T; Boudjemaa S; Leblanc T; Landman-Parker J
Bull Cancer; 2023 Sep; 110(9):968-977. PubMed ID: 37062647
[TBL] [Abstract][Full Text] [Related]
28. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
29. Nodular lymphocyte-predominant Hodgkin lymphoma.
Savage KJ; Mottok A; Fanale M
Semin Hematol; 2016 Jul; 53(3):190-202. PubMed ID: 27496311
[TBL] [Abstract][Full Text] [Related]
30. Hodgkin lymphoma with cutaneous involvement.
Hsia CC; Howson-Jan K; Rizkalla KS
Dermatol Online J; 2009 May; 15(5):5. PubMed ID: 19624983
[TBL] [Abstract][Full Text] [Related]
31. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
32. [Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].
Chen DB; Wang Y; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):635-6. PubMed ID: 21092597
[No Abstract] [Full Text] [Related]
33. Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: a syncytial variant.
Drakos E; Rassidakis GZ; Leventaki V; Cotta CV; Vega F; Medeiros LJ
Am J Surg Pathol; 2009 Nov; 33(11):1725-31. PubMed ID: 19730363
[TBL] [Abstract][Full Text] [Related]
34. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis.
Xing KH; Connors JM; Lai A; Al-Mansour M; Sehn LH; Villa D; Klasa R; Shenkier T; Gascoyne RD; Skinnider B; Savage KJ
Blood; 2014 Jun; 123(23):3567-73. PubMed ID: 24713929
[TBL] [Abstract][Full Text] [Related]
35. Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.
Bartlett NL
Hematology Am Soc Hematol Educ Program; 2005; ():245-51. PubMed ID: 16304388
[TBL] [Abstract][Full Text] [Related]
36. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
[TBL] [Abstract][Full Text] [Related]
37. Current developments in the treatment of early-stage classical Hodgkin lymphoma.
Borchmann S; von Tresckow B; Engert A
Curr Opin Oncol; 2016 Sep; 28(5):377-83. PubMed ID: 27455136
[TBL] [Abstract][Full Text] [Related]
38. How I treat nodular lymphocyte predominant Hodgkin lymphoma.
Advani RH; Hoppe RT
Blood; 2013 Dec; 122(26):4182-8. PubMed ID: 24215035
[TBL] [Abstract][Full Text] [Related]
39. [Nodular lymphocyte-predominant Hodgkin's lymphoma and differential diagnoses].
Hartmann S; Cogliatti S; Hansmann ML
Pathologe; 2013 May; 34(3):233-43. PubMed ID: 23494280
[TBL] [Abstract][Full Text] [Related]
40. The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma.
Halbsguth TV; Böll B; Borchmann P; Diehl V
Curr Hematol Malig Rep; 2011 Sep; 6(3):164-71. PubMed ID: 21553348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
